Published in Mol Pharmacol on July 01, 1998
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol (2002) 0.87
Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochem Pharmacol (2012) 0.87
Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res (2012) 0.83
Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol (2003) 0.81
Molecular Characterization of Lipopolysaccharide Binding to Human α-1-Acid Glycoprotein. J Lipids (2012) 0.78
Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms. J Biol Chem (2011) 0.78
On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography. Anal Bioanal Chem (2016) 0.75
Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations. J Mol Recognit (2012) 0.75
Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant. Drugs R D (2017) 0.75
Signs of the times: the need for a stereochemically informative generic name system. Trends Pharmacol Sci (1989) 2.67
In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol (2007) 1.78
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol (2007) 1.77
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet (2000) 1.76
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol (1982) 1.65
Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci (1984) 1.54
[Impact of CRP rapid test in management of febrile children in paediatric emergency units of Ile-de-France]. Arch Pediatr (2006) 1.53
Antipyretic efficacy of an initial 30-mg/kg loading dose of acetaminophen versus a 15-mg/kg maintenance dose. Pediatrics (2001) 1.51
A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin Pharmacol (1996) 1.44
Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev (1981) 1.42
[First intention management of obstructive sleep apnea syndrome (OSAS) by custom-made mandibular advancement device: the medium-term results. Prospective study by the General Hospital Pneumologists College (CPHG)]. Rev Pneumol Clin (2010) 1.40
Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf (1998) 1.39
Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem (2001) 1.35
Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem Pharmacol (1994) 1.35
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Falsely elevated intraocular pressure due to increased central corneal thickness. Graefes Arch Clin Exp Ophthalmol (1999) 1.29
Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem Pharmacol (1982) 1.29
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res (1996) 1.29
Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia (2011) 1.29
One-wedge convention for stereochemical representations. Enantiomer (2000) 1.27
Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res (1999) 1.26
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol (1984) 1.24
Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia (2010) 1.24
Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry (1999) 1.22
Outer membrane protein A (OmpA) binds to and activates human macrophages. J Immunol (2000) 1.18
Clofibrate and enzymatic induction in man. Int J Clin Pharmacol Biopharm (1978) 1.18
Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis (2007) 1.15
Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology (1990) 1.13
Paediatric varicella hospitalisations in France: a nationwide survey. Clin Microbiol Infect (2007) 1.13
Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem (1985) 1.11
Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet (1994) 1.11
Reliability of computed tomographic angiography in the diagnosis of brain death. Transplant Proc (2007) 1.10
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem (1991) 1.09
Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs (1996) 1.08
Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem (2000) 1.07
[Sinus bradycardia and sinoauricular block induced by carbamazepine]. Presse Med (1983) 1.07
Investigation of a new parameter in chronic lymphocytic leukemia: the percentage of large peripheral lymphocytes determined by the Hemalog D. Prognostic significance. Am J Med (1977) 1.06
Theoretical conformational studies on some dopamine antagonistic benzamide drugs: 3-pyrrolidyl- and 4-piperidyl derivatives. J Med Chem (1983) 1.06
Influence of sex on drug kinetics in man. Clin Pharmacokinet (1977) 1.06
Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther (1997) 1.05
The distribution of bound propranolol between the different human serum proteins. Mol Pharmacol (1980) 1.05
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem (1993) 1.05
Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci (2002) 1.05
Sexual victimization in women with schizophrenia and bipolar disorder. Soc Psychiatry Psychiatr Epidemiol (1995) 1.05
Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol (1984) 1.04
Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol (1998) 1.03
Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol (2001) 1.02
Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity (2000) 1.01
Diseases and drug protein binding. Clin Pharmacokinet (1978) 1.01
Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J Comput Aided Mol Des (1994) 1.01
Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React (1996) 1.00
Structural damage to proteins caused by free radicals: asessment, protection by antioxidants, and influence of protein binding. Biochem Pharmacol (2001) 1.00
Prediction of distribution coefficient from structure. 1. Estimation method. J Pharm Sci (1997) 1.00
Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin. Clin Pharmacol Ther (1986) 1.00
E-state fields: applications to 3D QSAR. J Comput Aided Mol Des (1996) 0.99
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Mol Pharmacol (1986) 0.99
Randomized, double-blind, multicenter, controlled trial of ibuprofen versus acetaminophen (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children. J Pediatr (1991) 0.99
X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore. J Med Chem (1995) 0.99
Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol (1974) 0.98
Critical risk/benefit analysis of pefloxacine use in children under 15 years--the problem of arthralgias. Int J Clin Pharmacol Ther Toxicol (1987) 0.97
Human effector memory T cells express CD86: a functional role in naive T cell priming. J Immunol (1999) 0.96
Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol (1993) 0.96
Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem (2000) 0.95
Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol (1999) 0.95
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1991) 0.94
Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test. Pediatr Res (1988) 0.94
Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther Drug Monit (1983) 0.94
A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm (1987) 0.93
Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. J Pharm Sci (1991) 0.93
Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol (1985) 0.92
The binding of aryl carboxylic acid derivatives to human serum albumin--a structure-activity study. Biochem Pharmacol (1984) 0.92
In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res (2001) 0.92
Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit (1988) 0.92
Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol (1998) 0.92
In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs (2000) 0.91
New insights into the second generation antihistamines. Drugs (2001) 0.91
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet (1990) 0.91
Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res (1996) 0.91
Metabolic chiral inversion of ibuprofen in isolated rat hepatocytes. Chirality (1990) 0.91
Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metab Dispos (2000) 0.90
Screening of dental staff nurses for noise induced hearing loss. B-ENT (2011) 0.90
Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett (2001) 0.89
Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Life Sci (1998) 0.89